In addition to the question of how to classify the latest test results on benzoyl peroxide (BPO) preparations used in acne treatment, the results of clinical studies on bimekizumab and new drug candidates such as vilobelimab and LAD191 in hidradenitis suppurativa (HS) were presented.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Atopic Dermatitis: Precisely Targeting Immunological Targets
Interleukin blockade or OX40-(L) inhibition?
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Across All Types of Cancer
Four-Legged Medical Assistants – Therapy Dogs in Clinical Settings
- Obesity: More than half of those affected have fatty liver disease
From screening to multimodal intervention with GLP-1-RA or resmetirom
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Interstitial Lung Diseases